arabian
peninsula
date
approv
medic
countermeasur
mcm
avail
combat
merscov
infect
sever
neutral
human
monoclon
antibodi
mab
includ
germlinelik
human
mab
chosen
promis
mcm
merscov
howev
clinic
develop
hinder
lack
robust
anim
model
recapitul
morbid
mortal
human
infect
assess
prophylact
therapeut
efficaci
use
wellcharacter
transgen
mice
shown
highli
sensit
merscov
infect
diseas
found
mice
treat
prior
post
lethal
merscov
challeng
fulli
protect
compar
control
mice
suffer
profound
weight
loss
uniform
death
within
day
infect
taken
togeth
result
support
develop
human
monoclon
antibodi
potenti
therapeut
merscov
infect
scientif
report
doi
longterm
threat
peopl
particularli
interact
close
camel
arabian
peninsula
even
though
merscov
present
limit
humantohuman
transmiss
high
mortal
rate
viru
limit
inform
mechan
abl
confer
increas
humantohuman
transmiss
rais
concern
potenti
mer
pandem
inde
recent
outbreak
korea
appear
superspread
event
indic
merscov
abil
caus
larg
outbreak
outsid
arabian
peninsula
current
approv
vaccin
drug
avail
treat
viral
infect
fact
highlight
urgent
need
develop
potent
prophylact
therapeut
agent
fight
lethal
viru
similar
coronavirus
merscov
use
envelop
spike
glycoprotein
class
transmembran
protein
interact
cellular
receptor
bind
fusion
entri
target
cell
receptor
bind
domain
rbd
locat
domain
merscov
spike
respons
bind
wellcharacter
cellular
receptor
identifi
therefor
critic
bind
entri
viru
therefor
neutral
antibodi
capabl
block
interact
could
promis
prevent
andor
therapeut
candid
recent
human
monoclon
antibodi
mab
capabl
neutral
merscov
identifi
character
sever
research
group
antibodi
isol
naiv
human
antibodi
librari
transgen
human
mice
b
cell
infect
individu
recogn
differ
epitop
merscov
rbd
one
potent
mab
germlinelik
antibodi
identifi
larg
size
phagedisplay
antibodi
librari
deriv
b
cell
healthi
donor
mab
exhibit
except
potent
neutral
activ
ic
gml
vitro
moreov
epitop
almost
complet
overlap
receptorbind
site
merscov
rbd
evid
recent
solv
crystal
structur
probabl
gener
resist
mutant
may
absent
low
notabl
although
function
mab
extens
character
vitro
clinic
develop
hinder
lack
effect
anim
model
merscov
infect
merscov
infect
small
laboratori
anim
eg
mice
hamster
ferret
consequ
speciesspecif
differ
caus
mildtomoder
symptom
rhesu
macaqu
marmoset
suscept
merscov
develop
moderatetosever
diseas
limit
avail
high
cost
hamper
use
rabbit
infect
infecti
viru
challeng
detect
found
express
human
could
overcom
lack
suscept
normal
mice
prior
transduct
adenovir
human
vector
mice
becam
suscept
merscov
infect
without
reveal
measur
clinic
manifest
contrast
transgen
tg
mice
human
gene
integr
genom
readili
develop
acut
morbid
weight
loss
uniform
death
occur
within
week
make
ideal
preclin
model
develop
vaccin
treatment
mer
aforement
human
neutral
monoclon
antibodi
shown
protect
engin
human
mice
natur
permiss
rabbit
entir
base
abil
inhibit
merscov
infect
andor
allevi
histopatholog
lung
verifi
protect
efficaci
human
monoclon
antibodi
particularli
merscov
infect
highli
desir
use
wellcharacter
human
tg
mice
known
result
acut
diseas
weight
loss
death
use
highli
permiss
tg
mous
model
evalu
prophylact
therapeut
efficaci
mab
vivo
report
studi
first
time
treatment
tg
mice
singledos
antibodi
prior
challeng
ld
merscov
protect
mice
lethal
dosedepend
manner
therebi
repres
first
antibodi
test
protect
efficaci
lethal
merscov
infect
prophylact
efficaci
merscov
rbdspecif
human
monoclon
antibodi
establish
tg
mous
model
profoundli
sensit
suscept
merscov
infect
determin
high
viral
titer
lung
well
high
rate
morbid
mortal
equip
small
anim
model
human
merscov
investig
protect
efficaci
mab
accomplish
group
n
mice
treat
via
intraperiton
ip
rout
two
differ
dose
mg
mg
per
mous
dilut
l
pb
challeng
intranas
h
post
treatment
tcid
ie
ld
merscov
volum
l
challeng
mice
monitor
daili
clinic
manifest
weight
loss
mortal
shown
fig
group
treat
mg
mab
surviv
viral
infect
without
show
clinic
symptom
mice
initi
show
either
weight
loss
recov
mild
weight
loss
within
three
day
fig
hand
group
treat
mg
mab
show
gradual
weight
loss
day
start
recov
fig
surviv
mice
one
die
day
mice
treat
mg
continu
recov
appear
well
dpi
experi
termin
fig
merscovchalleng
mice
pretreat
high
dose
mg
irrelev
mab
exhibit
profound
weight
loss
succumb
infect
mortal
day
pi
fig
b
therapeut
efficaci
merscov
rbdspecif
human
monoclon
antibodi
determin
therapeut
potenti
human
monoclon
antibodi
group
mice
n
per
group
challeng
tcid
merscov
ie
ld
volum
l
treat
ip
hour
later
singl
dose
either
mg
mg
mg
antibodi
control
l
per
mous
follow
monitor
daili
wellb
weight
loss
clinic
manifest
mortal
mice
note
wherea
treatment
mg
antibodi
effect
protect
lethal
caus
merscov
infect
fail
protect
mice
fulli
onset
clinic
ill
weight
loss
specif
challeng
mice
treat
mg
antibodi
suffer
attenu
transient
weight
loss
day
gradual
recov
day
experi
termin
fig
similarli
challeng
mice
treat
low
dose
mg
antibodi
suffer
attenu
transient
weight
loss
day
pi
gradual
recov
howev
note
singl
death
day
low
dose
treatment
group
fig
expect
mice
treat
singl
dose
mg
control
antibodi
exhibit
profound
weight
loss
succumb
merscov
infect
mortal
day
pi
fig
taken
togeth
result
indic
merscov
rbdspecif
human
antibodi
highli
effect
prophylact
therapeut
modal
protect
highli
permiss
transgen
mice
merscov
infect
diseas
also
investig
protect
mechan
merscov
determin
lung
viru
titer
challeng
mice
day
treatment
specif
sacrif
two
mice
group
describ
fig
lung
specimen
harvest
determin
viral
titer
use
via
vero
cellbas
infect
assay
quantit
pcr
qpcr
base
assay
target
upstream
e
gene
merscov
shown
fig
unabl
recov
infecti
viru
mous
treat
mg
antibodi
either
challeng
merscov
howev
abl
detect
bare
detect
infecti
viru
limit
detect
lod
log
ticd
g
singl
mous
receiv
mg
prior
viral
challeng
result
indic
mab
like
confer
protect
lethal
challeng
restrict
viral
replic
within
lung
therebi
prevent
viral
infect
brain
organ
titer
viral
rna
copi
number
shown
qrtpcr
assay
also
compar
among
group
differ
dose
mab
lung
infect
mice
harvest
day
postand
previru
challeng
group
group
exhibit
detect
viral
rna
titer
significantli
lower
control
group
group
pretreat
group
mice
treat
mg
show
reduct
viral
rna
detect
log
reduct
viral
number
seen
mice
treat
within
mg
compar
mice
receiv
control
mab
posttreat
group
smaller
log
differ
viral
rna
copi
number
compar
pretreat
group
observ
mice
treat
mg
antibodi
compar
receiv
control
antibodi
log
reduct
viral
rna
number
seen
mice
treat
mg
compar
mice
receiv
control
mab
fig
data
indic
confer
signific
protect
mice
administ
preor
postvir
challeng
taken
togeth
result
suggest
us
epitop
target
except
potent
rbdspecif
antibodi
great
potenti
develop
potent
prevent
therapeut
agent
futur
treatment
attenu
lung
patholog
associ
merscov
infect
effect
antibodi
treatment
pulmonari
patholog
associ
merscov
infect
evalu
use
formalinfix
paraffin
embed
hematoxylineosin
h
e
stain
lung
specimen
harvest
day
pi
pulmonari
patholog
note
mice
treat
differ
dose
control
antibodi
either
viral
infect
sever
scale
none
mild
moder
sever
h
estain
sampl
mice
pretreat
mg
mg
antibodi
grade
respect
perivascular
intraalveolar
infiltr
mononuclear
cell
includ
lymphocyt
macrophagesmonocyt
fig
middl
panel
wherea
obtain
mice
receiv
postinfect
lung
specimen
collect
day
viral
challeng
process
assess
viral
titer
use
vero
infect
assay
qrtpcr
target
upstream
e
gene
merscov
express
log
tcid
gram
log
tcid
equival
eq
gram
respect
prophylact
therapeut
efficaci
human
antibodi
treatment
reduc
lung
titer
infecti
viru
b
prophylact
therapeut
efficaci
human
antibodi
reduc
titer
viral
rna
data
shown
repres
least
two
independ
conduct
assay
use
sampl
data
present
mean
standard
error
se
p
determin
use
student
test
scientif
report
doi
treatment
either
dose
grade
fig
right
panel
compar
grade
assign
mice
receiv
control
antibodi
treatment
prior
infect
fig
left
panel
merscov
attract
signific
basic
research
clinic
studi
sinc
first
discov
earli
even
though
transmiss
merscov
among
human
remain
low
present
mutationpron
rna
viru
could
eventu
evolv
highli
communic
virul
human
pathogen
emphas
urgent
need
develop
effect
antivir
therapi
could
restrict
spread
deadli
diseas
viral
infect
neutral
antibodi
shown
protect
host
diseas
progress
andor
reduc
sever
clinic
symptom
passiv
immunotherapi
prophylaxi
treatment
infecti
viral
diseas
wide
use
mani
decad
passiv
transfer
neutral
antibodi
also
promis
strategi
prophylaxi
treatment
merscov
infect
end
other
success
demonstr
protect
efficaci
specif
human
neutral
monoclon
antibodi
anim
model
merscov
infect
among
panel
merscovspecif
mab
gener
use
vast
phage
display
librari
identifi
three
mab
specif
bind
merscov
rbd
high
affin
among
three
identifi
note
mab
exhibit
highest
potenc
neutral
live
merscov
character
novel
human
mab
tg
mous
model
merscov
infect
show
prophylact
therapeut
protect
mice
treat
lethal
challeng
viru
respect
thu
mab
highli
promis
potent
inhibitor
urgent
prophylaxi
adjunct
treatment
patient
infect
merscov
studi
note
passiv
transfer
mg
mg
monoclon
antibodi
individu
mice
h
prior
challeng
ld
merscov
result
protect
lethal
respect
fig
suggest
use
mg
prophylaxi
suboptim
complet
neutral
viral
infect
therebi
allow
residu
virus
replic
within
lung
cours
infect
data
demonstr
confer
dosedepend
reduct
merscov
infect
corrobor
lower
viral
rna
level
live
viru
isol
determin
mice
compar
control
mice
studi
also
confirm
therapeut
efficaci
dosedepend
manner
similar
prophylact
studi
administr
singledos
antibodi
concentr
either
mg
per
mous
h
merscov
challeng
provid
protect
respect
infectioninduc
lethal
accompani
reduc
viral
load
infecti
viru
viral
rna
within
lung
howev
also
note
recoveri
bodyweight
loss
reduct
viral
load
mice
treat
mg
hr
infect
slower
treat
mg
shown
fig
respect
clear
evid
show
advers
impact
overal
wellb
mice
impos
upon
treatment
mg
antibodi
merscov
challeng
fig
difficult
complet
rule
exist
subtl
yettob
investig
highdos
drug
toxic
specul
subtl
highdos
drug
toxic
phase
acut
dynam
merscov
infect
initi
hr
treatment
mg
could
exacerb
drug
toxic
result
reduct
appetit
antivir
capac
howev
neg
impact
impos
upon
highdos
treatment
viral
infect
mice
appear
transient
irrevers
alter
final
outcom
infect
judg
mortal
fig
addit
studi
especi
pharmacokinet
dose
frequenc
warrant
futur
optim
prevent
therapeut
strategi
promis
antibodi
transgen
mice
use
evalu
prophylact
especi
therapeut
efficaci
antibodi
extrem
sensit
merscov
infect
diseas
ld
id
tcid
merscov
respect
data
shown
titer
lower
origin
estim
strike
abil
antibodi
prophylact
therapeut
agent
significantli
protect
transgen
mice
challeng
ld
merscov
highli
impress
rbd
merscov
target
antibodi
highli
conserv
among
variou
clinic
isol
mutat
rate
rbd
appear
extrem
low
compar
rna
virus
therebi
make
develop
escap
mutant
unlik
howev
combin
treatment
multipl
neutral
mab
target
differ
epitop
merscovspecif
fusion
inhibitor
target
domain
subunit
merscov
protein
could
desir
immun
mice
rbd
merscov
protein
li
et
al
recent
develop
human
mab
name
exhibit
strong
neutral
activ
nd
gml
pseudotyp
live
merscov
respect
less
potent
nd
gml
pseudotyp
live
merscov
respect
use
mous
model
demonstr
intraven
administr
singl
dose
one
day
merscov
challeng
result
reduct
viral
titer
log
dpi
howev
intraperiton
administr
tg
mice
lead
reduct
viral
titer
high
log
dpi
sinc
merscov
challeng
mice
show
sever
diseas
effect
weight
loss
mortal
mice
unavail
addit
unlik
transgen
mice
use
studi
welldefin
express
well
lethal
dose
ld
infecti
dose
id
intens
express
among
mice
variabl
rang
undetect
high
level
although
bind
rbd
merscov
protein
critic
amino
acid
residu
recogn
two
mab
differ
epitop
overlap
extens
site
compos
merscov
rbd
residu
epitop
mab
parent
mous
mab
overlap
partial
site
compos
five
rbd
residu
rbd
amino
acid
recogn
includ
locat
site
indic
neutral
efficaci
larg
attribut
steric
hindranc
creat
bind
merscov
rbd
result
suggest
combin
use
may
exhibit
synergist
antivir
effect
wildtyp
strain
escap
mutant
merscov
taken
togeth
result
suggest
us
merscov
rbd
proteinspecif
mab
excel
candid
passiv
immunotherapi
provid
immedi
effect
protect
individu
may
expos
merscov
treat
patient
expos
test
human
need
potenti
use
therapeut
treatment
merscovinfect
patient
monoclon
antibodi
product
express
previous
describ
vector
use
infect
cell
atcc
manassa
va
polyfect
transfect
reagent
qiagen
valencia
ca
screen
clone
antibodi
product
elisa
subsequ
character
stabl
cell
line
gener
inocul
bioflo
bioreactor
new
brunswick
scientif
nj
largescal
product
purif
carri
use
protein
g
column
ge
healthcar
endotoxin
remov
detoxigel
endotoxin
remov
column
thermo
scientif
accord
manufactur
instruct
transgen
mice
express
human
establish
us
use
throughout
studi
anim
hous
onsit
anim
facil
galveston
nation
laboratori
lightdark
cycl
room
temperatur
humid
kept
respect
ad
libitum
access
food
water
experi
perform
accord
guid
nih
aaalac
approv
institut
anim
care
use
committe
univers
texa
medic
branch
describ
previous
briefli
group
tg
mice
challeng
intranas
tcid
ml
ld
origin
provid
heinz
feldmann
nih
niaid
rocki
mountain
laboratori
hamilton
mt
ron
fouchier
erasmu
medic
center
rotterdam
netherland
titer
individu
viru
stock
store
determin
use
vero
infect
assay
express
tissu
cultur
infecti
dose
tcid
ml
scientif
report
doi
viral
infect
isol
anim
studi
involv
infecti
merscov
conduct
within
approv
anim
biosafeti
level
galveston
nation
laboratori
experiment
design
strategi
differ
tg
mous
group
involv
intranas
challeng
live
merscov
describ
individu
experi
result
section
live
viru
isol
lung
tissu
collect
day
post
merscov
challeng
weigh
homogen
phosphatebuff
salin
pb
contain
fetal
calf
serum
fc
use
tissuelys
qiagen
retsch
haan
germani
previous
describ
result
suspens
infect
tissu
titter
standard
vero
cellbas
infect
assay
quantifi
yield
infecti
viru
express
log
tcid
per
gram
g
tissu
rna
extract
viral
titer
determin
realtim
qpcr
lung
tissu
sampl
group
mice
transfer
individu
vial
rna
later
solut
qiagen
subsequ
homogen
subject
total
rna
isol
use
trizol
reagent
life
technolog
assess
merscovspecif
genom
target
virusspecif
upstream
e
gene
upe
endogen
control
gene
mous
actin
use
onestep
rtpcr
kit
invitrogen
previous
describ
ct
valu
sampl
analyz
ct
valu
gener
lab
standard
curv
merscov
mrna
copi
number
rel
merscov
upe
mrna
express
valu
calcul
replic
express
equival
tcid
per
gram
g
tissu
standard
threshold
cycl
method
ct
valu
analysi
done
use
biorad
cfx
manag
softwar
